Anlotinib plus penpulimab has demonstrated encouraging activity and safety in a phase 2 study. In this phase 3 trial, we aimed to assess whether the combination of anlotinib plus penpulimab improved ...

SES AUA 2025 phase 1 trial of mevrometostat (PF-06821497), mevrometostat with enzalutamide plus ADT, abiraterone.

Instil Bio plans to start a phase 1 trial of AXN-2510 for solid tumors following FDA IND clearance.

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) that target estrogen receptors through new mechanisms, highlighting modest ...

Panelists discuss the EMBER-3 trial, which evaluated single-agent oral selective estrogen receptor degrader (SERD) imlunestrant vs standard endocrine therapy and the combination of imlunestrant with ...

The detailed results of DREAMS-1 and another Phase 3 study (DREAMS-2), which compared mazdutide with dulaglutide combined with oral hypoglycemic drugs in Chinese T2D patients, will also be ...